A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The Japanese Study Group for Pediatric Liver Tumor (JPLT) has conducted cooperative treatment studies on hepatoblastoma (HBL) since 1991. The JPLT2 protocol was launched in 1999 to evaluate the efficacy of cisplatin/pirarubicin (CITA) under risk stratification. European and North American groups showed the improvement of HBL patients by pre- and postoperative chemotherapeutic regimens. Therefore, we evaluated the results of JPLT study and considered the future aspect of JPLT.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Pediatr. Surg. Int.

Title: Pediatric surgery international

Publisher: Springer Nature America, Inc

ISSN (Electronic): 1437-9813

ISSN (Print): 0179-0358

Publication date (Electronic): Oct 2013

Volume: 29

Issue: 10

Affiliations

[1 ] Department of Pediatric Surgery, Hiroshima University Hospital, Hiroshima, Japan, eiso@hiroshima-u.ac.jp.

Article

DOI: 10.1007/s00383-013-3399-0

PubMed ID: 24026876

SO-VID: 881ba33d-53c6-4057-80a5-f052a5f86a0a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 6

See all cited by